TY - JOUR
KW - Administration, Sublingual
KW - Adult
KW - Buprenorphine/administration & dosage
KW - Female
KW - Humans
KW - Male
KW - Naloxone/administration & dosage
KW - Narcotic Antagonists/administration & dosage
KW - Opioid-Related Disorders/therapy
KW - Retrospective Studies
KW - Substance Abuse Treatment Centers
AU - J. M. Soeffing
AU - D. A. Rastegar
A1 - 
AB - PURPOSE: Buprenorphine is commonly used for opioid detoxification. The goal of this study was to determine whether a change from the intramuscular (IM) buprenorphine to the sublingual (SL) formulation of buprenorphine-naloxone was associated with improved treatment completion rates on an inpatient detoxification unit. METHODS: This study was conducted at the Johns Hopkins Bayview Medical Center (JHBMC) Chemical Dependence Unit (CDU), a 26-bed, 3-day inpatient detoxification unit providing detoxification from opioids, alcohol, and sedatives. The opioid detoxification protocol was changed from IM buprenorphine (0.3 mg bid for 3 days) to SL buprenorphine-naloxone (8, 8, and 6 mg on sequential days, plus 2 mg on the morning of discharge). For the 3 months prior to and after the change in protocol, data were collected retrospectively on demographics, type of dependence being treated, and type of discharge. FINDINGS: A total of 1,168 patients were admitted to the JHBMC CDU during the period studied. In the 3 months prior to the change in buprenorphine protocol, 353 of 483 patients admitted for treatment of opioid dependence (73.1%) completed treatment, compared with 407 of 473 patients admitted after the change (86.0%); this difference was highly significant (p < .0001). Among 212 patients who did not receive treatment for opioid dependence over the same period, the rates of treatment completion did not change significantly (89.8% before vs. 83.0% after; p = .208). CONCLUSIONS: A change from IM buprenorphine to SL buprenorphine-naloxone for opioid detoxification was associated with a significant improvement in completion rates at this inpatient treatment program.
BT - Journal of substance abuse treatment
C5 - Opioids & Substance Use
CP - 4
CY - United States
IS - 4
JF - Journal of substance abuse treatment
N2 - PURPOSE: Buprenorphine is commonly used for opioid detoxification. The goal of this study was to determine whether a change from the intramuscular (IM) buprenorphine to the sublingual (SL) formulation of buprenorphine-naloxone was associated with improved treatment completion rates on an inpatient detoxification unit. METHODS: This study was conducted at the Johns Hopkins Bayview Medical Center (JHBMC) Chemical Dependence Unit (CDU), a 26-bed, 3-day inpatient detoxification unit providing detoxification from opioids, alcohol, and sedatives. The opioid detoxification protocol was changed from IM buprenorphine (0.3 mg bid for 3 days) to SL buprenorphine-naloxone (8, 8, and 6 mg on sequential days, plus 2 mg on the morning of discharge). For the 3 months prior to and after the change in protocol, data were collected retrospectively on demographics, type of dependence being treated, and type of discharge. FINDINGS: A total of 1,168 patients were admitted to the JHBMC CDU during the period studied. In the 3 months prior to the change in buprenorphine protocol, 353 of 483 patients admitted for treatment of opioid dependence (73.1%) completed treatment, compared with 407 of 473 patients admitted after the change (86.0%); this difference was highly significant (p < .0001). Among 212 patients who did not receive treatment for opioid dependence over the same period, the rates of treatment completion did not change significantly (89.8% before vs. 83.0% after; p = .208). CONCLUSIONS: A change from IM buprenorphine to SL buprenorphine-naloxone for opioid detoxification was associated with a significant improvement in completion rates at this inpatient treatment program.
PP - United States
PY - 2007
SN - 0740-5472; 0740-5472
SP - 401
EP - 404
EP - 
T1 - Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone
T2 - Journal of substance abuse treatment
TI - Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone
U1 - Opioids & Substance Use
U2 - 17400414
VL - 33
VO - 0740-5472; 0740-5472
Y1 - 2007
ER -